- Home
- IVA vs KNDI Comparison
IVA vs KNDI Comparison
Compare IVA & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVA
- KNDI
- Stock Information
- Founded
- IVA 2011
- KNDI 2002
- Country
- IVA France
- KNDI China
- Employees
- IVA N/A
- KNDI N/A
- Industry
- IVA Biotechnology: Pharmaceutical Preparations
- KNDI Auto Manufacturing
- Sector
- IVA Health Care
- KNDI Consumer Discretionary
- Exchange
- IVA Nasdaq
- KNDI Nasdaq
- Market Cap
- IVA 162.8M
- KNDI N/A
- IPO Year
- IVA 2020
- KNDI N/A
- Fundamental
- Price
- IVA $3.05
- KNDI $1.39
- Analyst Decision
- IVA Strong Buy
- KNDI
- Analyst Count
- IVA 4
- KNDI 0
- Target Price
- IVA $13.25
- KNDI N/A
- AVG Volume (30 Days)
- IVA 8.1K
- KNDI 177.4K
- Earning Date
- IVA 03-26-2025
- KNDI 05-15-2025
- Dividend Yield
- IVA N/A
- KNDI N/A
- EPS Growth
- IVA N/A
- KNDI N/A
- EPS
- IVA N/A
- KNDI N/A
- Revenue
- IVA $15,243,814.00
- KNDI $118,127,232.00
- Revenue This Year
- IVA $18.05
- KNDI N/A
- Revenue Next Year
- IVA $46.74
- KNDI N/A
- P/E Ratio
- IVA N/A
- KNDI N/A
- Revenue Growth
- IVA N/A
- KNDI N/A
- 52 Week Low
- IVA $1.53
- KNDI $0.89
- 52 Week High
- IVA $3.98
- KNDI $2.98
- Technical
- Relative Strength Index (RSI)
- IVA 56.16
- KNDI 47.53
- Support Level
- IVA $2.88
- KNDI $1.31
- Resistance Level
- IVA $3.10
- KNDI $1.44
- Average True Range (ATR)
- IVA 0.17
- KNDI 0.09
- MACD
- IVA -0.01
- KNDI -0.02
- Stochastic Oscillator
- IVA 77.27
- KNDI 30.77
Stock Price Comparison Chart: IVA vs KNDI
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.